Technical Analysis for PLX - Protalix BioTherapeutics, Inc.

Grade Last Price % Change Price Change
C 4.64 -4.92% -0.24
PLX closed up 0.21 percent on Tuesday, March 2, 2021, on 75 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down
Historical PLX trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish -4.92%
Wide Bands Range Expansion -4.92%
Oversold Stochastic Weakness -4.92%
20 DMA Resistance Bearish -4.72%
Stochastic Reached Oversold Weakness -4.72%
Wide Bands Range Expansion -4.72%
Oversold Stochastic Weakness -4.72%
20 DMA Resistance Bearish -5.31%
Wide Bands Range Expansion -5.31%
Fell Below 20 DMA Bearish -3.93%
Older End-of-Day Signals for PLX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 5% about 2 hours ago
10 DMA Resistance about 2 hours ago
Down 3% about 2 hours ago
Down 2 % about 3 hours ago
Fell Below Previous Day's Low about 3 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Protalix BioTherapeutics, Inc. Description

Protalix BioTherapeutics, Inc., a biopharmaceutical company, together with its subsidiary, Protalix Ltd., focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system. It offers taliglucerase alfa for injection, which is marketed under the ELELYSO brand name, as an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. The company's product pipeline includes PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-105, a plant cell expressed pegylated recombinant acetylcholinesterase product candidate for biodefense and other indications; and an orally-administered glucocerebrosidase enzyme for the treatment of Gaucher patients utilizing oral delivery of the recombinant enzyme produced within carrot cells. Its product pipeline also comprises PRX-106 or pr-antiTNF, a plant cell expressed recombinant fusion protein made from the soluble form of the human TNF receptor and an antibody portion, which is being developed as a treatment of certain immune diseases, such as rheumatoid arthritis, Chrohn's disease, placque psoriasis, and other autoimmune disorders; and two additional undisclosed therapeutic proteins that are being evaluated in animal studies. It has a collaboration and licensing agreement with Teva Pharmaceutical Industries Ltd. to develop and manufacture two proteins using its ProCellEx protein expression system. The company was founded in 1993 and is based in Carmiel, Israel.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Biology Rheumatoid Arthritis Psoriasis Immune Disorders Pharmaceutical Industries Autoimmune Disorders Fusion Protein Choline Biodefense Teva Pharmaceutical Industries Enzyme Replacement Therapy Fabry Disease Gaucher Disease Cholinesterase Recombinant Dna Acetylcholine Treatment Of Fabry Disease

Is PLX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 7.02
52 Week Low 2.0362
Average Volume 828,955
200-Day Moving Average 3.80
50-Day Moving Average 4.38
20-Day Moving Average 5.09
10-Day Moving Average 4.99
Average True Range 0.48
ADX 45.73
+DI 30.98
-DI 14.92
Chandelier Exit (Long, 3 ATRs ) 5.57
Chandelier Exit (Short, 3 ATRs ) 5.67
Upper Bollinger Band 6.11
Lower Bollinger Band 4.06
Percent B (%b) 0.4
BandWidth 40.35
MACD Line 0.14
MACD Signal Line 0.22
MACD Histogram -0.0802
Fundamentals Value
Market Cap 162.68 Million
Num Shares 33.3 Million
EPS -0.17
Price-to-Earnings (P/E) Ratio -28.05
Price-to-Sales 1.40
Price-to-Book 0.00
PEG Ratio -0.10
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.52
Resistance 3 (R3) 5.56 5.39 5.41
Resistance 2 (R2) 5.39 5.23 5.37 5.38
Resistance 1 (R1) 5.14 5.13 5.26 5.09 5.34
Pivot Point 4.97 4.97 5.03 4.95 4.97
Support 1 (S1) 4.71 4.81 4.84 4.67 4.42
Support 2 (S2) 4.54 4.71 4.52 4.38
Support 3 (S3) 4.29 4.54 4.35
Support 4 (S4) 4.24